Ultimate magazine theme for WordPress.

BioHarvest Sciences signs agreement with Royal Emerald Pharmaceuticals for cannabis research

0



BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share news the company has as signed a binding letter of intent with Royal Emerald Pharmaceuticals. This company is only one of seven Drug Enforcement Administration bulk-manufacturing registration holders permitted to grow marijuana in the United States for drug-related studies.

Sobel telling Proactive the partnership will run for 3 years and allows for unique and patentable cannabis compositions to be used for research into treatment of any number of conditions.

#proactivinvestors #cse #bhsc #otcqb #cnvcf #pharma #biotech

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

source

Leave A Reply

Your email address will not be published.